Cordycepin Reverses Cisplatin Resistance in Non-Small Cell Lung Cancer by Activating AMPK and Inhibiting the AKT Signaling Pathway

Xiaozhong Liao(Southern Medical University), Lizhu Lin(Guangzhou University of Chinese Medicine)
Research Square (Research Square)
September 23, 2020
10.21203/rs.3.rs-76670/v1
Cited by 0

Related Papers

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Network pharmacology based research into the effect and mechanism of Yinchenhao Decoction against Cholangiocarcinoma
|Chinese Medicine|2021|95
Tanshinone IIA combined with cisplatin synergistically inhibits non‐small‐cell lung cancer in vitro and in vivo via down‐regulating the phosphatidylinositol 3‐kinase/Akt signalling pathway
|Phytotherapy Research|2019|64
Matrine combined with cisplatin synergistically inhibited urothelial bladder cancer cells via down-regulating VEGF/PI3K/Akt signaling pathway
|Cancer Cell International|2017|62
Negative association of C-reactive protein-albumin-lymphocyte index (CALLY index) with all-cause and cause-specific mortality in patients with cancer: results from NHANES 1999–2018
|BMC Cancer|2024|45